Literature DB >> 19947892

Pharmacology and clinical use of voriconazole.

George R Thompson1, James S Lewis.   

Abstract

IMPORTANCE OF THE FIELD: Voriconazole is an extended-spectrum triazole developed specifically to target Aspergillus spp. and is now indicated as primary therapy in this circumstance. However, it has a broad spectrum of activity against both yeasts and molds and is also a viable treatment option in the treatment of other mycoses. AREAS COVERED IN THIS REVIEW: This review discusses the mechanism of action, the pharmacodynamics and pharmacokinetics and the most common mechanisms of resistance to this agent. An overview of therapeutic drug monitoring, drug-drug interactions and pivotal trials are also reviewed. WHAT THE READER WILL GAIN: The reader will gain further knowledge of the unique aspects of voriconazole compared to other currently available antifungal agents. TAKE HOME MESSAGE: Voriconazole offers distinct advantages over several other antifungals. The side effect profile of voriconazole is unique compared to other triazole agents. Concern for drug-drug interactions due to a frequently shared common metabolic pathway has prompted heightened interest in the use of therapeutic drug monitoring for concerns of toxicity, drug-drug interactions and in attempts to ensure efficacy. These aspects as well as a review of important clinical information pertaining to voriconazole are discussed here.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19947892     DOI: 10.1517/17425250903463878

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  14 in total

Review 1.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

2.  Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection.

Authors:  Ikuko Nakamura; Ryuichi Kanasaki; Koji Yoshikawa; Shigetada Furukawa; Akihiko Fujie; Hiroshi Hamamoto; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2016-08-31       Impact factor: 2.649

3.  Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort.

Authors:  George R Thompson; Charles R Krois; Verena K Affolter; Angela D Everett; E Katarina Varjonen; Victoria R Sharon; Anil Singapuri; Michael Dennis; Ian McHardy; Hong Sik Yoo; Dawn M Fedor; Nathan P Wiederhold; Phylicia A Aaron; Angie Gelli; Joseph L Napoli; Stephen D White
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.

Authors:  Johan G C van Hasselt; Natasha K A van Eijkelenburg; Alwin D R Huitema; Jan H M Schellens; Antoinette Y N Schouten-van Meeteren
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

5.  Invasive fungal infection of the central nervous system in a patient with acute myeloid leukaemia.

Authors:  Anna Janik-Moszant; Aleksander Matyl; Iwona Rurańska; Agnieszka Machowska-Majchrzak; Ewa Kluczewska; Tomasz Szczepański
Journal:  Pol J Radiol       Date:  2012-01

Review 6.  Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.

Authors:  Pierre-Régis Burgel; André Paugam; Dominique Hubert; Clémence Martin
Journal:  Infect Drug Resist       Date:  2016-09-20       Impact factor: 4.003

7.  In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice.

Authors:  Genki Kimura; Takahiro Nakaoki; Thomas Colley; Garth Rapeport; Pete Strong; Kazuhiro Ito; Yasuo Kizawa
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections.

Authors:  Yuanming Xing; Lu Chen; Yan Feng; Yan Zhou; Yajing Zhai; Jun Lu
Journal:  BMC Infect Dis       Date:  2017-12-28       Impact factor: 3.090

9.  Fungal malignant otitis externa with facial nerve palsy: tissue biopsy AIDS diagnosis.

Authors:  Jenny Walton; Chris Coulson
Journal:  Case Rep Otolaryngol       Date:  2014-02-05

Review 10.  Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections.

Authors:  Monica A Donnelley; Elizabeth S Zhu; George R Thompson
Journal:  Infect Drug Resist       Date:  2016-06-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.